Portal Innovations and New Brunswick Development Corporation Partner with Johnson & Johnson to Launch the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Strengthening New Jersey’s Position as a Leading Life Sciences and Innovation Center
Portal Innovations, in collaboration with New Brunswick Development Corporation and HELIX, has announced that Johnson & Johnson has secured naming rights to the Johnson & Johnson Exchange at the New Jersey Innovation Hub (NJIH), Powered by Portal Innovations. The initiative represents a significant expansion of New Jersey’s life sciences and innovation ecosystem and highlights growing collaboration between major healthcare corporations, startup incubators, academic institutions, and economic development organizations.
The New Jersey Innovation Hub is scheduled to open in Spring 2026 and will operate as a 30,000-square-foot science incubator located within the HELIX innovation district in downtown New Brunswick. The facility is being developed to support early-stage life sciences startups by providing flexible laboratory infrastructure, office space, specialized programming, and access to investment and commercialization networks designed to accelerate scientific innovation from discovery through clinical and commercial development.
The newly named Johnson & Johnson Exchange will serve as the incubator’s central collaboration and gathering space. According to the organizations involved, the Exchange is expected to host a broad range of events throughout the year, including founder workshops, investor forums, networking programs, industry panels, and community engagement initiatives focused on strengthening collaboration across New Jersey’s healthcare and biotechnology sectors.
The collaboration reflects Johnson & Johnson’s longstanding presence in New Jersey and its continued commitment to supporting innovation and entrepreneurship within one of the nation’s largest and most concentrated biotechnology ecosystems. For more than a century, the company has played a major role in shaping healthcare innovation in the state through pharmaceutical research, medical technology development, manufacturing investment, and academic partnerships.
The New Jersey Innovation Hub is intended to provide a centralized environment where entrepreneurs, scientists, investors, and corporate leaders can work together to accelerate the development of breakthrough healthcare technologies. By combining laboratory infrastructure with strategic programming and corporate engagement, the initiative aims to reduce many of the barriers faced by early-stage life sciences companies.
Under the partnership, Johnson & Johnson will not only lend its name to the central Exchange space but will also sponsor targeted innovation initiatives within the incubator. These programs are expected to focus on high-impact areas of scientific and entrepreneurial development while helping strengthen New Brunswick’s growing life sciences and startup community.
Mikie Sherrill, Governor of New Jersey, described the initiative as part of the state’s broader effort to position itself as a leading destination for startups, entrepreneurs, and healthcare innovators. She stated that New Jersey continues to expand investments in innovation infrastructure and strategic development projects designed to support entrepreneurship and scientific advancement.
According to Governor Sherrill, facilities such as HELIX and the New Jersey Innovation Hub are helping drive breakthroughs in healthcare and life sciences while also supporting long-term economic growth and job creation across the region. She added that the collaboration between Johnson & Johnson, Portal Innovations, and DEVCO demonstrates the importance of public-private partnerships in building sustainable innovation ecosystems.
Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, highlighted the company’s deep roots in New Jersey and its history of healthcare innovation spanning more than 140 years.
Duato stated that the Johnson & Johnson Exchange reflects the company’s belief that transformative ideas can emerge from a wide range of innovators and organizations. He emphasized that collaboration among industry leaders, entrepreneurs, and academic researchers can accelerate medical breakthroughs that improve patient outcomes while also supporting economic development and employment opportunities.
The partnership also illustrates a growing trend within the healthcare and biotechnology sectors in which major pharmaceutical and medical technology companies increasingly engage directly with startup incubators and early-stage innovation hubs. Such collaborations allow large healthcare organizations to gain early access to emerging technologies, scientific talent, and novel therapeutic concepts while supporting broader ecosystem development.
Industry experts increasingly view these types of partnerships as strategically important because they create opportunities for established corporations to identify promising technologies, form research collaborations, and potentially support future acquisition or licensing opportunities. At the same time, startup companies benefit from access to mentorship, capital networks, industry expertise, and commercialization guidance.
The New Jersey Innovation Hub is being developed by DEVCO as part of the broader HELIX innovation district, a mixed-use development initiative designed to bring together research institutions, healthcare systems, academic organizations, technology companies, and commercial partners in downtown New Brunswick.
Chris Paladino, President of DEVCO, stated that the project aligns closely with New Jersey’s long-term vision for inclusive economic growth and innovation-focused development. He noted that the Johnson & Johnson Exchange is expected to become a central hub for collaboration and entrepreneurial activity within the region’s life sciences community.
Paladino explained that the collaboration among Portal Innovations, Johnson & Johnson, and DEVCO reflects a shared commitment to creating infrastructure capable of supporting the next generation of scientific entrepreneurs and startup companies.
The initiative has also received support from the New Jersey Economic Development Authority. Evan Weiss, CEO of the organization, said Johnson & Johnson’s investment in the Innovation Hub demonstrates the type of strategic corporate leadership needed to strengthen New Jersey’s life sciences ecosystem.
Weiss noted that the NJEDA previously supported HELIX through Aspire funding awards and Strategic Innovation Center investments aimed at fostering economic development and scientific commercialization. According to Weiss, the partnership further reinforces New Brunswick’s growing reputation as a premier destination for healthcare innovation and life sciences entrepreneurship.
He added that the collaboration is expected to help transform scientific discoveries into commercial opportunities while generating high-quality employment opportunities for residents across the state.
Portal Innovations will play a central operational and strategic role in the New Jersey Innovation Hub. The company, which focuses on venture development within the life sciences sector, is helping design the incubator to address increasing demand for affordable, high-quality laboratory space and hands-on support for early-stage biotechnology companies.
The organization has built a reputation for creating innovation environments that combine physical infrastructure with operational support, mentorship, and investor connectivity. Such resources are increasingly important for emerging biotechnology companies, many of which face substantial financial and operational barriers during early development stages.
Upon the opening of NJIH, Sangeetha Ramsagar will oversee day-to-day laboratory and office operations at the facility, helping manage programming and startup engagement activities.
John Flavin, Founder and CEO of Portal Innovations, described Johnson & Johnson as one of the most recognizable names in global healthcare innovation. He stated that the company’s presence within the Innovation Hub sends a strong signal to entrepreneurs and scientists building businesses within the region.
Flavin emphasized that successful scientific entrepreneurship depends not only on funding but also on access to world-class infrastructure, collaborative communities, and strategic corporate partnerships. According to him, the partnership reinforces a shared belief among all participating organizations that integrated innovation ecosystems are essential for translating scientific discoveries into real-world healthcare solutions.
The science incubator at NJIH is expected to support startups operating across multiple healthcare sectors, including therapeutics, medical devices, diagnostics, and enabling technologies. By serving a broad range of life sciences disciplines, the facility aims to become a central node within New Jersey’s expanding biotechnology ecosystem.
New Jersey has long been recognized as one of the leading pharmaceutical and biotechnology centers in the United States, home to numerous global healthcare companies, academic institutions, and research organizations. State leaders and industry stakeholders have increasingly focused on strengthening startup infrastructure and innovation networks in order to maintain competitiveness within the rapidly evolving global life sciences industry.
The launch of the New Jersey Innovation Hub reflects broader trends shaping the future of healthcare innovation, including the increasing importance of interdisciplinary collaboration, translational research, and public-private partnerships. As scientific discoveries become more complex and commercialization timelines more demanding, innovation ecosystems capable of connecting startups with investors, corporations, researchers, and healthcare systems are becoming increasingly valuable.
By establishing the Johnson & Johnson Exchange at the New Jersey Innovation Hub, the participating organizations aim to create an environment where scientific entrepreneurship can thrive while supporting the broader growth of New Jersey’s life sciences economy.
As the facility prepares to open in 2026, stakeholders expect the incubator to play an important role in helping early-stage healthcare companies accelerate development, attract investment, and advance breakthrough technologies capable of improving patient care globally. Through a combination of laboratory infrastructure, corporate collaboration, investor access, and entrepreneurial programming, the initiative is positioned to strengthen New Jersey’s standing as a major center for healthcare innovation and biotechnology advancement.
